CAR-T therapies

Oncology

ADCs shine at ESMO ’23, as pharma makes case for early immun...

Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical Oncology (ESMO) Congress in Madrid 20th-24th October, which was back at full capac

News

CARGO eyes $300m IPO against lacklustre listings backdrop

CARGO Therapeutics has said it plans to offer around 18.8 million shares in the latest bid by a biotech to list on the Nasdaq, amid a desultory year for initial public off

News

ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours?

CAR-T therapies have transformed the treatment of some haematological cancers, but haven’t made much headway for solid tumours – although BioNTech thinks it may have the k

Oncology

Combining new and existing immunity: A 3D approach to killin...

A question which has long baffled scientists, frustrated clinicians, and devastated patients is why the immune system so effectively defends against infections, but so poorly deals with can

Oncology

Five takeaways from the CAR-TCR cell therapy conference

Last week, I had the privilege of heading into town in Boston to attend three days of the CAR-TCR conference, a major annual gathering of researchers and industry stakeholders concerned wit

News

Astellas adds to cell therapy drive with Poseida deal

Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.

ADCs shine at ESMO ’23, as pharma makes case for early immun...

CARGO eyes $300m IPO against lacklustre listings backdrop

ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours?

Combining new and existing immunity: A 3D approach to killin...

Five takeaways from the CAR-TCR cell therapy conference

Astellas adds to cell therapy drive with Poseida deal

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

CAR-T therapies

Editor's Picks